BusinessCidara Provides Corporate Update and Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 10, 2017, 9:07 PM UTC
BusinessSelecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other CancersBy Nasdaq OMXMay 2, 2017, 12:00 PM UTC
BusinessNeoTherma Oncology Announces FDA Granted Its Vectron Thermal Device for Treatment of Pancreatic Cancer Breakthrough Device Designation within Expedited Access PathwayBy Nasdaq OMXApr 4, 2017, 2:06 PM UTC
BusinessPeregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of ImmunotherapyBy Nasdaq OMXApr 4, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target ToxicitiesBy Nasdaq OMXApr 3, 2017, 12:05 PM UTC
BusinessCidara Therapeutics to Host Investor Day on April 6, 2017By Nasdaq OMXMar 29, 2017, 11:33 AM UTC
BusinessPeregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual MeetingBy Nasdaq OMXMar 23, 2017, 11:05 AM UTC
BusinessCidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 15, 2017, 9:23 PM UTC
